Beneficial effects of vincamine with thioctic acid and lutein on retinal and optic nerve functions in an opaque media
Author:
Corresponding Author:

Sameh Saleh. Ophthalmology Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. yohaahmed12@yahoo.com

  • Article
  • | |
  • Metrics
  • |
  • Reference [25]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To detect whether the combination of vincamine, thioctic acid and lutein will improve the retina and optic nerve functions in cases of an opaque media with an optic nerve and/or a retinal defect or not. METHODS: Totally 2000 patients (2000 eyes) of corneal opacities with defects in the optic nerve or/and the retinal functions were studied. Every patient received three types of drugs: thioctic acid with cyanocobalamine, vincamine, and lutein. The drugs were given daily for 3-12mo according to patient’s responses. Full field flash electroretinogram (ERG) and flash visual evoked potential (VEP) were done before treatment and at 1, 3, 6, and 12mo sequentially. Patients were followed up for 12mo. RESULTS: In the 2000 eyes, 1000 eyes had both moderate optic nerve and retinal function defects; and 840 eyes out of the 1000 improved with the medical treatment. Another 500 eyes out of the 2000 eyes had extinguished retinal function with normal optic nerve function and only 125 eyes of them improved. The 290 out of the 2000 eyes had severe defects in optic nerve with normal retinal function and 130 of them improved. Another 210 eyes have mild optic nerve and retinal function defects and 194 improved. CONCLUSION: The combination of vincamine, thioctic acid with cyanocobalamine, and lutein improved both retina and optic nerve functions mainly in mild and moderate defect than in severe cases.

    Reference
    1 Chous AP, Richer SP, Gerson JD, Kowluru RA. The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol 2016;100(2): 227-234.
    2 Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119(10):1417-1436.
    3 Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Tormene AP, Vaegan. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010;120(1):111-119.
    4 Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009;118(1):69-77.
    5 Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26(3):270-274.
    6 McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 2015;131(1):1-12.
    7 Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A, Tormene AP, International Society for Clinical Electrophysiology of Vision. ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 2016;133(1):1-9.
    8 Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Investig Ophthalmol Vis Sci 2012;53(12):7871-7880.
    9 Brazionis L, Rowley K, Itsiopoulos C, O’Dea K. Plasma carotenoids and diabetic retinopathy. Br J Nutr 2009;101(2):270-277.
    10 Burke JD, Curran-Celentano J, Wenzel AJ. Diet and serum carotenoid concentrations affect macular pigment optical density in adults 45 years and older. J Nutr 2005;135(5):1208-1214.
    11 Crosby-Nwaobi R, Hykin P, Peto T, Sivaprasad S. An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases. Clin Ophthalmol 2016;10:835-844.
    12 Jia YP, Sun L, Yu HS, Liang LP, Li W, Ding H, Song XB, Zhang LJ. The pharmacological effects of lutein and zeaxanthin on visual disorders and cognition diseases. Molecules 2017;22(4):E610.
    13 Bellezza I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. Front Pharmacol 2018;9:1280.
    14 Wu J, Cho E, Willett WC, Sastry SM, Schaumberg DA. Intakes of lutein, zeaxanthin, and other carotenoids and age-related macular degeneration during 2 decades of prospective follow-up. JAMA Ophthalmol 2015;133(12):1415-1424.
    15 Xue CY, Rosen R, Jordan A, Hu DN. Management of ocular diseases using lutein and zeaxanthin: what have we learned from experimental animal studies? J Ophthalmol 2015;2015:523027.
    16 Stringham JM, Stringham NT. Serum and retinal responses to three different doses of macular carotenoids over 12 weeks of supplementation. Exp Eye Res 2016;151:1-8.
    17 Buscemi S, Corleo D, Di Pace F, Petroni ML, Satriano A, Marchesini G. The effect of lutein on eye and extra-eye health. Nutrients 2018;10(9): E1321.
    18 Bernstein PS. The role of lutein and zeaxanthin in protection against age-related macular degeneration. Acta Hortic 2015(1106):153-160.
    19 Xu X, Lin X. Molecular mechanism of the protective effect of lutein against retinal damage induced by blue-light in rats. J Hyg Res 2010;39(6):689-692.
    20 Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004;11(9):1135-1146.
    21 Suh JH, Shenvi SV, Dixon BM, Liu HL, Jaiswal AK, Liu RM, Hagen TM. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 2004;101(10):3381-3386.
    22 Morikawa T, Yasuno R, Wada H. Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Lett 2001; 498(1):16-21.
    23 Torres MJ, Fierro A, Pessoa-Mahana CD, Romero-Parra J, Cabrera G, Faúndez M. Effect of alpha lipoic acid on leukotriene A4 hydrolase. Eur J Pharmacol 2017;799:41-47.
    24 Yildirim Z, Emmez H, Kale A. Protective effect of alpha-lipoic acid against ischemia-reperfusion injury in retina. Oxidation Communications 2014;37(2):555-562.
    25 Hasa D, Perissutti B, Grassi M, Chierotti MR, Gobetto R, Ferrario V, Lenaz D, Voinovich D. Mechanochemical activation of vincamine mediated by linear polymers: assessment of some “critical” steps. Eur J Pharm Sci 2013;50(1):56-68.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Abdelkader M, Saleh S, Mokbel T,/et al.Beneficial effects of vincamine with thioctic acid and lutein on retinal and optic nerve functions in an opaque media. Int J Ophthalmol 2019;12(9):1450-1455

Copy
Share
Article Metrics
  • Abstract:948
  • PDF: 669
  • HTML: 363
  • Cited by: 0
Publication History
  • Received:February 24,2019
  • Revised:June 26,2019
  • Online: August 02,2019